- CAR-T cell therapy is a revolutionary cancer treatment that modifies a patient’s T-cells to target and destroy cancer cells. It has shown high efficacy in treating certain types of leukemia, lymphoma, and multiple myeloma
- The demand for CAR-T cell therapy is rising due to increasing incidences of hematologic malignancies and promising outcomes in clinical trials
- North America is expected to dominate the CAR-T cell therapy market owing to strong R&D activities, high healthcare expenditure, and early adoption of advanced therapies
- Asia-Pacific is expected to be the fastest growing region in the CAR-T cell therapy market during the forecast period due to expanding biotechnology sectors and increasing cancer burden.
- Acute lymphocytic leukemia segment is expected to dominate the market with a market share of 30% due to high treatment responsiveness and ongoing clinical development. As one of the first approved indications for CAR-T therapy, it continues to drive market growth
